85622-73-7

Upstream product

• 98-68-0 4-methoxy-phenyl-sulphonyl chloride 
• 616-34-2 methoxycarbonylmethylamine 

Downstream Products

• 1425411-67-1 C₃₅H₅₈N₄O₁₈S 
• 1425411-61-5 C₅₀H₇₃N₃O₂₅S 
• 1425411-64-8 C₃₆H₅₉N₃O₁₈S 
• 1425411-51-3 C₁₆H₂₆N₂O₅S 
• 1425411-54-6 C₂₈H₃₇N₃O₁₀S 
• 1425411-48-8 C₂₄H₃₂N₂O₇S 

Relevant academic research and scientific papers

First insight into structure-activity relationships of selective meprin β inhibitors

The astacin proteases meprin α and β are emerging drug targets for treatment of disorders such as kidney failure, fibrosis or inflammatory bowel disease. However, there are only few inhibitors of both proteases reported to date. Starting from NNGH as lead

SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION

This patent document diclsoes novel compounds and methods of preventing or treating diseases or conditions related to Keapl-Nrf2 interaction activity by use of the novel compounds. As direct inhibitors of Keapl-Nrf2 interaction, the compounds disclosed herein are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential dmg candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, Parkinson's, and inflammatory bowel disease including ulcerative colitis.